Prime Capital Investment Advisors LLC Has $6.32 Million Stake in Amgen Inc. $AMGN

Prime Capital Investment Advisors LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 23.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,318 shares of the medical research company’s stock after buying an additional 3,711 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Amgen were worth $6,323,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Capital World Investors raised its position in Amgen by 11.5% during the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares in the last quarter. National Bank of Canada FI boosted its stake in shares of Amgen by 237.7% in the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after purchasing an additional 863,216 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Amgen by 71.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock valued at $383,254,000 after purchasing an additional 567,400 shares in the last quarter. Fisher Asset Management LLC boosted its stake in shares of Amgen by 91.6% in the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock valued at $221,607,000 after purchasing an additional 375,463 shares in the last quarter. Finally, Danske Bank A S acquired a new stake in shares of Amgen in the 3rd quarter valued at approximately $101,076,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMGN has been the topic of a number of research analyst reports. TD Cowen restated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Barclays assumed coverage on shares of Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price target for the company. Mizuho upped their price target on shares of Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Argus upped their price target on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target for the company. in a report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus price target of $355.16.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Phase‑3 data for a subcutaneous/on‑body TEPEZZA injector showed strong efficacy and safety vs IV, potentially enabling at‑home dosing and broader use for Thyroid Eye Disease — this could expand TEPEZZA’s addressable market and improve convenience-driven uptake. Amgen’s TEPEZZA Injector Data Sparks Questions On Value And Competition
• Positive Sentiment: Royal Bank of Canada lifted its price target to $370, a bullish signal that supports upside versus prior analyst levels and may underpin buying interest. Royal Bank Of Canada Increases Amgen Price Target to $370
• Positive Sentiment: Investors continue to focus on Amgen’s push into GLP‑1/obesity (MariTide — move to a once‑quarterly injectable was highlighted), which positions the company in a high‑growth segment and complements its existing biologics portfolio. We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play.
• Neutral Sentiment: Analysts/market pieces note recent share gains and market outperformance, reflecting broader healthcare strength and momentum rather than company‑specific catalysts alone. Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
• Neutral Sentiment: Guggenheim and Cantor Fitzgerald have maintained/reaffirmed neutral ratings ($351 and $350 targets respectively), signaling limited near‑term upside from their perspectives and keeping sentiment mixed. Guggenheim Adjusts Amgen Price Target Cantor Fitzgerald Reaffirms Neutral
• Negative Sentiment: Morgan Stanley kept a Hold and a $309 target, highlighting limited near‑term upside and providing a counterweight to bullish notes — this could pressure sentiment if investors focus on valuation gaps. Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating
• Negative Sentiment: Competitive pressure from Eli Lilly (and other GLP‑1 leaders) and debates over IMID positioning remain a risk to market share and pricing power in obesity/immunology categories. Eli Lilly Vs. Amgen: Who Leads Obesity And IMIDs

Amgen Stock Up 1.7%

Shares of NASDAQ:AMGN opened at $355.60 on Friday. The company has a fifty day moving average of $363.69 and a 200-day moving average of $334.30. The company has a market capitalization of $191.91 billion, a PE ratio of 24.99, a price-to-earnings-growth ratio of 3.47 and a beta of 0.47. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.